BMS-986525
PreclinicalSmall molecule
Bristol-Myers SquibbBMS-986525 is one of 10 small molecule programs targeting Small Cell Lung Carcinoma. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Small Cell Lung Carcinoma
#DrugCompanyPhaseTrials
1Imfinzi
AstraZenecaPhase 3
Opdivo
Bristol-Myers SquibbPhase 2
Tarlatamab-Dznl
AmgenPhase 2
Vepesid
AAvyxa
Phase 2
Paraplatin
AAvyxa
Phase 2
Tecentriq
RochePreclinical
SHR-1316
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 1
Pumitamig
Bristol-Myers SquibbPreclinical
BL-M14D1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 1
BMS-986525
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BMS-986525. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company